The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Mar. 29, 9:35 AM

Slide #4. Stoke Therapeutics, Inc. Secondary Offering

Company: Stoke Therapeutics, Inc. (NASDAQ:STOK)
Date announced: 3/26/2024
Shares Offered: 9,259,287
Date of Pricing: 3/27/2024
Price Per Share: $13.50
Secondary Offering Details: Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by Stoke. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 3/27- Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses payable by Stoke. The offering is expected to close on or about April 2, 2024, subject to the satisfaction of customary closing conditions. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares of common stock in connection with the offering. All of the shares of common stock and pre-funded warrants are being offered by Stoke.

Stoke Therapeutics is a biotechnology company focused on treating the underlying causes of severe genetic diseases by upregulating protein expression. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Co. is developing antisense oligonucleotides to selectively restore protein levels. Co.'s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Co.'s second product candidate, STK-002, is in development for treatment of Autosomal Dominant Optic Atrophy.

STOK SEC Filing Email Alerts Service

Open the STOK Page at The Online Investor »

Company Name: 
Stoke Therapeutics Inc
Website: 
www.stoketherapeutics.com
Sector: 
Biotechnology
Number of ETFs Holding STOK: 
14
Total Market Value Held by ETFs: 
$34.17M
Total Market Capitalization: 
$476.00M
% of Market Cap. Held by ETFs: 
7.18%
 

Open the STOK Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree STOK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.67 out of 4)
65th percentile
(ranked higher than approx. 65% of all stocks covered)

Analysts' Target Price:
STOK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.